Co announced that the FDA granted Fast Track designation to OMS824, the company's phosphodiesterase 10 (PDE10) inhibitor, for the treatment of cognitive impairment in patients with Huntington's disease. OMS824 selectively inhibits PDE10, an enzyme expressed in areas of the brain linked to a wide range of diseases that affect cognition, including Huntington's disease and schizophrenia. Omeros has conducted successful clinical trials assessing the safety, tolerability, pharmacokinetics and target engagement of a wide range of doses of OMS824 in its Phase 1 program. Positive data from the company's OMS824 Phase 2a schizophrenia trial were recently announced, and Omeros expects to begin enrolling patients this quarter in its Phase 2 trial evaluating OMS824 for Huntington's disease.
"Together with the orphan drug status previously awarded OMS824 by the FDA for Huntington's, we have the opportunity to streamline the development of this promising compound. We look forward to enrolling patients in our OMS824 Phase 2 clinical trial for Huntington's disease within the next few weeks."
Recent OMER News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/07/2024 08:08:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/07/2024 08:06:56 PM
- Omeros Corporation Reports Second Quarter 2024 Financial Results • Business Wire • 08/07/2024 08:02:00 PM
- Omeros Corporation to Announce Second Quarter Financial Results on August 7, 2024 • Business Wire • 08/05/2024 08:02:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/12/2024 08:48:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/07/2024 09:13:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/07/2024 09:12:17 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/07/2024 09:10:59 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/07/2024 09:08:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/07/2024 09:07:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/07/2024 09:05:53 PM
- Omeros Announces Webcast Details for Annual Meeting of Shareholders • Business Wire • 06/04/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/03/2024 01:00:24 PM
- Omeros Corporation Further Strengthens its Balance Sheet through Series of Financing Transactions Extending Maturity on a Majority of its Outstanding Debt into 2028 • Business Wire • 06/03/2024 01:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2024 08:09:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2024 08:07:40 PM
- Omeros Corporation Reports First Quarter 2024 Financial Results • Business Wire • 05/15/2024 08:02:00 PM
- Omeros Corporation to Announce First Quarter Financial Results on May 15, 2024 • Business Wire • 05/10/2024 12:50:00 PM
- Omeros Corporation Announces Upcoming Presentations at 2024 European Hematology Association (EHA) Hybrid Congress • Business Wire • 05/09/2024 12:50:00 PM
- Omeros Corporation Reports Fourth Quarter and Year-End 2023 Financial Results • Business Wire • 04/01/2024 08:02:00 PM
- Omeros Corporation to Announce Fourth Quarter and Year-End Financial Results on April 1, 2024 • Business Wire • 03/27/2024 12:30:00 PM
- Omeros Corporation Announces Upcoming Presentation Detailing Narsoplimab Compassionate Use in Nine Patients with Hematopoietic Stem Cell Transplant-associated Thrombotic Microangiopathy • Business Wire • 02/20/2024 02:00:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 11:05:17 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/07/2024 01:00:23 PM
- Omeros Corporation Announces Additional Royalty Monetization with DRI Healthcare Trust • Business Wire • 02/01/2024 02:11:00 PM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM